Kuno K, Ogawa A, Hayakawa F, Ito K, Kondo M, Okumura A, Natsume J
Department of Pediatrics, Anjo Kosei Hospital.
Jpn J Antibiot. 1993 Nov;46(11):1017-24.
Clinical studies on S-1108, a new oral cephem antibiotic, were carried out in the field of pediatrics. The following results were obtained. 1. The peak plasma level of S-1006 when administered after meal at a dose of 4 mg/kg was 2.47 micrograms/ml at an hour, and the serum half-life was 0.81 hour. The 4 hours urinary excretion rate of S-1006 was 35.7%. 2. S-1108 was administered to 15 children with various infections (3 patients with pneumonia, 3 with acute bronchitis, 4 with scarlet fever, 2 with acute tonsillitis, 1 with phlegmon and 2 with urinary tract infections). The overall clinical efficacy rate was 100%. 3. Side effects or abnormal laboratory test values were not observed except for diarrhea in 1 and eosinophilia in 1.
对新型口服头孢菌素抗生素S - 1108进行了儿科领域的临床研究。获得了以下结果。1. 餐后以4mg/kg的剂量给药时，S - 1006的血浆峰值水平在1小时时为2.47微克/毫升，血清半衰期为0.81小时。S - 1006的4小时尿排泄率为35.7%。2. 对15名患有各种感染的儿童（3例肺炎、3例急性支气管炎、4例猩红热、2例急性扁桃体炎、1例蜂窝织炎和2例尿路感染）给予S - 1108。总体临床有效率为100%。3. 除1例腹泻和1例嗜酸性粒细胞增多外，未观察到副作用或实验室检查值异常。
